The Gynecologic Cancer Intergroup (GCIG): History and current status

Annals of Oncology

Volumn 16, Issue SUPPL. 8, 2005, Pages

  Vermorken, Jan B ^a   Avall Lundqvist, E ^b   Pfisterer, J ^c   Bacon, M ^d  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

CANCER RELAPSE; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; FEMALE; HEALTH EDUCATION; HEALTH PROMOTION; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL COOPERATION; MEDICAL LITERATURE; MEDICAL SOCIETY; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL;

FEMALE; GENITAL NEOPLASMS, FEMALE; GYNECOLOGY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERNATIONAL COOPERATION; MEDICAL ONCOLOGY;

EID: 27744511344     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi966     Document Type: Conference Paper

References (28)

1. Brady MF, Thigpen JT, Vermorken JB, Parmar MKB. Randomised trials in ovarian cancer: Trial design considerations. Ann Oncol 1999; 10 (Suppl 1): 75-82.
2. Markman M. Single agent carboplatin is the treatment of choice in recurrent, potentially platinum-sensitive epithelial ovarian cancer. ASCO Educational Book 2002, Lippincott Williams & Wilkins, Baltimore, MD, pp. 521-523.
3. Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant Chemotherapy in Ovarian Neoplasm trial: Two parallel randomized phase trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-112.
4. Biago JJ, Eisenhauer EA. Systematic treatment policies in ovarian cancer: The next 10 years. Int J Gynecol Cancer 2003; 13 (Suppl 2): 231-240.
5. Piccart MJ, Stuart GCE, Cassidy J et al. Intergroup collaboration in ovarian cancer: A giant step forward. Ann Oncol 1999; 10 (Suppl 1): 83-86.
6. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. BMJ 1991; 303: 884-893.
7. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses from 37 individual trials. Br J Cancer 1998; 78: 1479-1487.
8. ICON Collaborators. ICON2: Randomised trial of single agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. International Collaborative Ovarian Neoplasm Study. Lancet 1998; 352: 1571-1576.
9. International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomized trial. Lancet 2002; 360: 505-515.
10. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2000; 18: 106-115.
11. Vermorken JB, on behalf of the Gynecologic Cancer Intergroup. Intergroup collaboration in ovarian cancer: The Gynecologic Cancer Intergroup (GCIG). Int J Gynecol Cancer 2001; 11 (Suppl 1): 73-76.
12. Berek JS, Bertelsen K, du Bois A et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10 (Suppl 1): 87-92.
13. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-2666.
14. McGuire WP, Hoskins WJ, Brady MF et al. A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 1993; 12: 255 (Abstr 808).
15. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
16. Piccart MJ, Bertelsen K, James K et al. Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000; 92: 699-708.
17. Rothenberg M, Liu PY, Braly PS et al. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: Results from an intergroup phase II trial. J Clin Oncol 2003; 21: 1313-1319.
18. du Bois A, Weber B, Pfisterer et al. Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cnacer FIGO stages IIB-IV. Interim results of an AGO-GINECO Intergroup phase III trial. Proc Am Soc Clin Oncol 2001; 20: 202a (Abstr 805).
19. du Bois A, Combe J, Rochon C et al. Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line tratment of ovarian cancer (OC) FIGO stage IIB-IV. An AGO-GINECO Intergroup phase III trial. J Clin Oncol 2004; 22: 450 (Abstr 5007).
20. Vergote I, Rustin GJ, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2000; 92: 18: 1534-1535.
21. Rustin GJS, Quin M, Thigpen T et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004; 96: 487-488.
22. Kristensen G, Vergote I, Stuart G et al. First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-NCIC CTG Gynecologic Cancer Intergroup phase III trial. Proc Am Soc Clin Oncol 2002; 21: 202a (Abstr 805).
23. Kristensen GB, Vergote I, Stuart G et al. First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 2003; 13 (Suppl 2): 172-177.
24. Kristensen GB, Vergote I, Eisenhauer E et al. First line treatment of ovarian/tubal/peritoneal cancer FIGO stages IIb-IV with paclitaxel/ carboplatin with or without epirubicin (TEC vs TC). J Clin Oncol 2004; 22: 449 (Abstr 5003).
25. Pfisterer J, Lortholary A, Kimmig R et al. Paclitaxel/carboplatin (TC) VS. paclitaxel/carboplatin followed by topotecan (TC-Top) in first line treatment of ovarian cancer FIGO stages IIb-IV. Interim results of a gynecologic cancer intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO. Proc Am Soc Clin Oncol 2003; 22: 446 (Abstr 1793).
26. Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: Carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5. Int J Gynecol Cancer 2003; 13 (Suppl 2): 149-155.
27. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventinal platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
28. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol 2004; 22: 450 (Abstr 5005).